Story perspectives

ImmunityBio Reviews Promotions Following FDA Warning on ANKTIVA

4/6/2026

Summary

Story summary

ImmunityBio, Inc. announced a review of its promotional materials and compliance after an FDA warning about ANKTIVA.
The company said a problematic TV advertisement was never aired and it removed a related podcast.
Richard Adcock, CEO of ImmunityBio, stressed commitment to accurate promotional communications.
A securities fraud class action against ImmunityBio alleges misstatements about ANKTIVA; it covers Jan 19, 2026 to Mar 24, 2026, with a May 26, 2026 deadline.

1 of 1

Story summary

ImmunityBio, Inc. announced a review of its promotional materials and compliance after an FDA warning about ANKTIVA.
The company said a problematic TV advertisement was never aired and it removed a related podcast.
Richard Adcock, CEO of ImmunityBio, stressed commitment to accurate promotional communications.
A securities fraud class action against ImmunityBio alleges misstatements about ANKTIVA; it covers Jan 19, 2026 to Mar 24, 2026, with a May 26, 2026 deadline.